
    
The genomic variant c.126_129del p.Phe42LeufsTer19, also known as rs1235072590, is located on the HBB gene, which encodes the beta-globin subunit of hemoglobin. Hemoglobin is a critical protein in red blood cells that carries oxygen from the lungs to the rest of the body and returns carbon dioxide from the tissues back to the lungs. The HBB gene is essential for the proper function of hemoglobin and, consequently, for the effective transport of oxygen.The c.126_129del p.Phe42LeufsTer19 variant results in the deletion of four nucleotides, leading to a frameshift and the creation of a premature termination codon at the 19th amino acid position downstream from the mutation site. This frameshift mutation is predicted to cause nonsense-mediated mRNA decay, which would likely result in a loss of normal protein function [1]. The variant has been reported in individuals with a relevant phenotype, specifically beta-thalassemia, a blood disorder that reduces the production of hemoglobin [1].In a study examining mutations in patients with thalassemia, the c.126_129del p.Phe42LeufsTer19 variant was identified as one of the heterozygous mutations present in the HBB gene [1]. Another study found this variant to be the most common HBB gene mutation, present in 34 alleles (23.8%) among the alleles studied, excluding the HbE mutation [2]. This variant has been associated with beta-thalassemia disease, with cases reported of both homozygous individuals and compound heterozygotes with other HBB gene mutations [2].A case study of a pregnant woman with a homozygous c.126_129del p.Phe42LeufsTer19 mutation revealed an unexpectedly mild phenotype of beta-thalassemia, which was attributed to high levels of Hb F and genetic modifiers that ameliorate the severity of the disease [3]. The patient's mild phenotype was also influenced by a KLF1 mutation and homozygous HBS1L-MYB variants, which are known to upregulate the expression of the gamma-globin gene and are associated with Hb F levels [3].The variant has been detected using various genetic analysis techniques, including reverse dot blot (RDB) method, DNA sequencing, and multiplex ligation-dependent probe amplification (MLPA) [3]. It has been characterized as a common beta0-thalassemia mutation in certain populations, with most homozygous patients presenting with a classic transfusion-dependent beta-thalassemia major phenotype [3].In summary, the c.126_129del p.Phe42LeufsTer19 variant in the HBB gene is a frameshift mutation that leads to a premature stop codon and is associated with beta-thalassemia. It is a pathogenic variant with multiple submissions in ClinVar supporting its role in disease. The presence of this variant can have significant clinical implications, particularly in homozygous or compound heterozygous states, and its detection is crucial for the diagnosis and management of beta-thalassemia.

ゲノム変異 c.126_129del p.Phe42LeufsTer19（rs1235072590としても知られる）は、ヘモグロビンのβグロビン亜単位をコードするHBB遺伝子に位置しています。ヘモグロビンは赤血球内の重要なタンパク質であり、肺から体全体に酸素を運び、組織から肺に二酸化炭素を戻す役割を果たします。HBB遺伝子はヘモグロビンの適切な機能、ひいては酸素の効果的な輸送に不可欠です。  
c.126_129del p.Phe42LeufsTer19変異は4つのヌクレオチドの欠失を引き起こし、フレームシフトを生じさせ、変異部位から下流の19番目のアミノ酸位置で早期終止コドンを生成します。このフレームシフト変異は、ナンセンス媒介mRNA分解を引き起こすと予測されており、正常なタンパク質機能の喪失をもたらす可能性が高いとされています[1]。この変異は、特にヘモグロビンの産生を減少させる血液疾患であるβサラセミアの表現型を持つ個人で報告されています[1]。  
サラセミア患者の変異を調査した研究では、c.126_129del p.Phe42LeufsTer19変異がHBB遺伝子に存在するヘテロ接合性変異の1つとして特定されました[1]。別の研究では、この変異が最も一般的なHBB遺伝子変異であることが判明し、研究対象の対立遺伝子のうち34対立遺伝子（23.8%）で検出されました（HbE変異を除く）[2]。この変異はβサラセミア疾患と関連しており、ホモ接合性個体および他のHBB遺伝子変異との複合ヘテロ接合性個体の両方の症例が報告されています[2]。  
ホモ接合性c.126_129del p.Phe42LeufsTer19変異を持つ妊婦の症例研究では、予想外に軽度のβサラセミア表現型が明らかになり、これはHb Fの高レベルおよび疾患の重症度を軽減する遺伝的修飾因子に起因するとされました[3]。患者の軽度の表現型は、KLF1変異およびホモ接合性HBS1L-MYB変異によっても影響を受けており、これらはガンマグロビン遺伝子の発現を上方制御し、Hb Fレベルと関連しています[3]。  
この変異は、リバースドットブロット（RDB）法、DNAシーケンシング、マルチプレックスリガンド依存プローブ増幅（MLPA）など、さまざまな遺伝子解析技術を使用して検出されています[3]。特定の集団では一般的なβ0-サラセミア変異として特徴付けられており、ほとんどのホモ接合性患者は古典的な輸血依存性βサラセミアメジャー表現型を示します[3]。  
まとめると、HBB遺伝子のc.126_129del p.Phe42LeufsTer19変異は、フレームシフト変異によって早期終止コドンを生じさせ、βサラセミアと関連しています。この変異は病原性変異として分類されており、ClinVarにおける複数の提出がその疾患における役割を支持しています。この変異の存在は、特にホモ接合性または複合ヘテロ接合性状態において、臨床的に重要な意味を持ち、βサラセミアの診断および管理においてその検出が重要です。
    
## References
- [1] Wan Y et al. (2024). "Prediction the Occurrence of Thalassemia With Hematological Phenotype by Diagnosis of Abnormal HbA1c." Journal of clinical laboratory analysis, 38(19-20) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39317177/)
- [2] Traivaree C et al. (2018). "Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis." Journal of blood medicine, 9() [PubMed](https://pubmed.ncbi.nlm.nih.gov/29695942/)
- [3] Jiwu L et al. (2021). "Hyperhaemolysis in a pregnant woman with a homozygous beta(0) -thalassemia mutation and two genetic modifiers." Molecular genetics & genomic medicine, 9(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33960744/)
- [4] Li H et al. (2019). "Noninvasive prenatal diagnosis of beta-thalassemia by relative haplotype dosage without analyzing proband." Molecular genetics & genomic medicine, 7(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31566929/)
- [5] Ju AP et al. (2022). "Hb Huadu [alpha124(H7)Ser-->Thr (TCC>ACC), HBA2: c.373T>A]: A Novel Variant of the alpha-Globin Gene." Hemoglobin, 46(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/36524388/)
- [6] Lee HJ et al. (2019). "Increased Prevalence of Thalassemia in Young People in Korea: Impact of Increasing Immigration." Annals of laboratory medicine, 39(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30430775/)
- [7] Zhang M et al. (2019). "[Variant analysis for patients from Fujian area with Hong Kong alphaalpha type thalassemia]." Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 36(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30950011/)
- [8] Xu L et al. (2020). "Long-Molecule Sequencing: A New Approach for Identification of Clinically Significant DNA Variants in alpha-Thalassemia and beta-Thalassemia Carriers." The Journal of molecular diagnostics : JMD, 22(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32473995/)
- [9] Qiu Y et al. (2020). "Compound Heterozygosity for a Novel Mutation Codon 104 (-A) (HBB: c.313delA) and Codons 41/42 (-CTTT) (HBB: c.126_129delCTTT) Leading to beta-Thalassemia Major in a Chinese Family." Hemoglobin, 44(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33198537/)
- [10] Chen M et al. (2020). "Hereditary spherocytosis overlooked for 7 years in a pediatric patient with beta-thalassemia trait and novel compound heterozygous mutations of SPTA1 gene." Hematology (Amsterdam, Netherlands), 25(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33210974/)
- [11] Jiang F et al. (2022). "beta-Thalassemia Intermedia Caused by the beta-Globin Gene 3' Untranslated Region: Another Case Report." Hemoglobin, 46(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35980111/)
- [12] Wen YJ et al. (2022). "Identification of a Novel Mutation in the 3' Untranslated Region of the beta-Globin Gene (HBB:c.*132C>G) in a Chinese Family." Hemoglobin, 46(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/36876863/)
- [13] So CC et al. (2011). "Hb A2 Hong Kong - A novel delta-globin variant in a Chinese family masks the diagnosis of beta-thalassemia trait." Hemoglobin, 35(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/21417575/)
- [14] Huang G et al. (2014). "Coexistence of two beta-globin gene deletions in a Chinese girl with beta-thalassemia minor." Hemoglobin, 38(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/24200214/)
- [15] Liu S et al. (2015). "Primer-introduced restriction analysis polymerase chain reaction method for non-invasive prenatal testing of beta-thalassemia." Hemoglobin, 39(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/25548039/)

    
## ClinVar Submissions
- **[RCV000020328](https://www.ncbi.nlm.nih.gov/clinvar/RCV000020328/)**: beta Thalassemia
- **[RCV000508554](https://www.ncbi.nlm.nih.gov/clinvar/RCV000508554/)**: not provided
- **[RCV002465488](https://www.ncbi.nlm.nih.gov/clinvar/RCV002465488/)**: Beta-thalassemia HBB/LCRB
- **[RCV001004569](https://www.ncbi.nlm.nih.gov/clinvar/RCV001004569/)**: Hb SS disease
- **[RCV001262999](https://www.ncbi.nlm.nih.gov/clinvar/RCV001262999/)**: Fetal hemoglobin quantitative trait locus 1
- **[RCV002426507](https://www.ncbi.nlm.nih.gov/clinvar/RCV002426507/)**: Inborn genetic diseases
- **[RCV002496380](https://www.ncbi.nlm.nih.gov/clinvar/RCV002496380/)**: Dominant beta-thalassemia (and 8 more)
- **[RCV003914848](https://www.ncbi.nlm.nih.gov/clinvar/RCV003914848/)**: HBB-related condition
- **[RCV000016673](https://www.ncbi.nlm.nih.gov/clinvar/RCV000016673/)**: Beta zero thalassemia

    